EURURO Vol. 72 No. 6

927 1030

cancer. J Clin Oncol 2005;23:7897–903
[4] Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after
androgen deprivation for prostate cancer. N Engl J Med
2005;352:154–64 .
[5] Thorstenson A, Bratt O, Akre O, et al. Incidence of fractures causing
hospitalisation in prostate cancer patients: results from the popu-
lation-based PCBaSe Sweden. Eur J Cancer 2012;48:1672–81.
.
[6] Tsai HK, D’Amico AV, Sadetsky N, Chen M-H, Carroll PR. Androgen
deprivation therapy for localized prostate cancer and the risk of
cardiovascular mortality. J Natl Cancer Inst 2007;99:1516–24.
.
[7] Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS.
Androgen deprivation therapy increases cardiovascular morbidity
inmen with prostate cancer. Cancer 2007;110:1493–500.
.
[8] Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and
duration of androgen deprivation for locally advanced prostate
cancer: analysis of RTOG 92-02. Eur Urol 2008;54:816–23.
.
[9] Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan
DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncol-
ogy and cardio-oncological prevention. J Natl Cancer Inst
2010;102:14–25
[10] Hayes JH, Chen M-H, Moran BJ, et al. Androgen-suppression therapy
for prostate cancer and the risk of death in men with a history of
myocardial infarction or stroke. BJU Int 2010;106:979–85
.
[11] Robinson D, Garmo H, Lindahl B, et al. Ischemic heart disease and
stroke before and during endocrine treatment for prostate cancer in
PCBaSe Sweden. Int J Cancer 2012;130:478–87
[12] O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van
Hemelrijck M. Risk and timing of cardiovascular disease after
androgen-deprivation therapy in men with prostate cancer. J Clin
Oncol 2015;33:1243–51
.
[13] Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and
relative risk of cardiovascular disease in men with prostate cancer:
results from the population-based PCBaSe Sweden. J Clin Oncol
2010;28:3448–56 .
[14] Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular
disease during androgen deprivation therapy for prostate cancer. J
Clin Oncol 2006;24:4448–56
[15] Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in
men with prostate cancer undergoing long-term androgen-depri-
vation therapy. J Clin Oncol 2006;24:3979–83
.
[16] Crawley D, Garmo H, Rudman S, et al. Association between duration
and type of androgen deprivation therapy and risk of diabetes in
men with prostate cancer. Int J Cancer 2016;139:2698–704
[17] Sun M, Choueiri TK, Hamnvik O-PR, et al. Comparison of gonado-
tropin-releasing hormone agonists and orchiectomy: effects of
androgen-deprivation therapy. JAMA Oncol 2016;2:500–7.
[18] Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy
in treatment of prostate cancer and risk of myocardial infarction
and stroke: a nationwide Danish population-based cohort study.
Eur Urol 2014;65:704–9
.
[19] Teoh JY, Chan SY, Chiu PK, et al. Risk of cardiovascular thrombotic
events after surgical castration versus gonadotropin-releasing hor-
mone agonists in Chinese men with prostate cancer. Asian J Androl
2014;17:493–6 .
[20]
[21] Wakefield J. Ecologic studies revisited. Annu Rev Public Health
2008;29:75–90
[22] Eloranta S, Adolfsson J, Lambert PC, et al. How can we make cancer
survival statistics more useful for patients and clinicians: an
illustration using localized prostate cancer in Sweden. Cancer
Causes Control 2013;24:505–15
.
[23] Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: the
National Prostate Cancer Register of Sweden and Prostate Cancer
Data Base Sweden 2.0. Int J Epidemiol 2013;42:956–67
[24] Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort
profile update: the National Prostate Cancer Register of Sweden and
Prostate Cancer Data Base—a refined prostate cancer trajectory. Int
J Epidemiol 2015;45:73–82 .
[25] Tomic K, Berglund A, Robinson D, et al. Capture rate and represen-
tativity of the National Prostate Cancer Register of Sweden. Acta
Oncol 2015;54:158–63
.
[26] Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P.
Evaluation of data quality in the National Prostate Cancer Register
of Sweden. Eur J Cancer 2015;51:101–11
.
[27]
.
[28] Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M.
Comorbidity, treatment and mortality: a population based cohort
study of prostate cancer in PCBaSe Sweden. J Urol 2011;185:833–9.
.
[29] Statistics Sweden. Longitudinal integration database for health
insurance and labour market studies (LISA by Swedish acronym).
[30] Fall K, Stromberg F, Rosell J, et al. Reliability of death certificates in
prostate cancer patients. Scand J Urol Nephrol 2008;42:352–7.
.
[31] Godtman R, Holmberg E, Stranne J, Hugosson J. High accuracy of
Swedish death certificates in men participating in screening for
prostate cancer: a comparative study of official death certificates
with a cause of death committee using a standardized algorithm.
Scand J Urol Nephrol 2011;45:226–32
[32]
[33] Thie´baut ACM, Be´nichou J. Choice of time-scale in Cox’s model
analysis of epidemiologic cohort data: a simulation study. Stat Med
2004;23:3803–20 .
[34] Ludvigsson JF, Andersson E, Ekbom A, et al. External review and
validation of the Swedish national inpatient register. BMC Public
Health 2011;11:450.
[35]
.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 2 0 – 9 2 8 927